Cardiac remodeling during and after renin–angiotensin system stimulation in Cyp1a1-Ren2 transgenic rats

This study investigated renin–angiotensin system (RAS)-induced cardiac remodeling and its reversibility in the presence and absence of high blood pressure (BP) in Cyp1a1-Ren2 transgenic inducible hypertensive rats (IHR). In IHR (pro)renin levels and BP can be dose-dependently titrated by oral administration of indole-3-carbinol (I3C). Young (four-weeks old) and adult (30-weeks old) IHR were fed I3C for four weeks (leading to systolic BP >200 mmHg). RAS-stimulation was stopped and animals were followed-up for a consecutive period. Cardiac function and geometry was determined echocardiographically and the hearts were excised for molecular and immunohistochemical analyses. Echocardiographic studies revealed that four weeks of RAS-stimulation incited a cardiac remodeling process characterized by increased left ventricular (LV) wall thickness, decreased LV volumes, and shortening of the left ventricle. Hypertrophic genes were highly upregulated, whereas in substantial activation a fibrotic response was absent. Four weeks after withdrawal of I3C, (pro)renin levels were normalized in all IHR. While in adult IHR BP returned to normal, hypertension was sustained in young IHR. Despite the latter, myocardial hypertrophy was fully regressed in both young and adult IHR. We conclude that (pro)renin-induced severe hypertension in IHR causes an age-independent fully reversible myocardial concentric hypertrophic remodeling, despite a continued elevated BP in young IHR.

[1]  B. Heijnen,et al.  Transient renin–angiotensin system stimulation in an early stage of life causes sustained hypertension in rats , 2011, Journal of hypertension.

[2]  G. Booz,et al.  New Take on the Role of Angiotensin II in Cardiac Hypertrophy and Fibrosis , 2011, Hypertension.

[3]  A. Danser,et al.  Handle Region Peptide Counteracts the Beneficial Effects of the Renin Inhibitor Aliskiren in Spontaneously Hypertensive Rats , 2011, Hypertension.

[4]  J. Mullins,et al.  Transient Induction of ANG II-Dependent Malignant Hypertension Causes Sustained Elevation of Blood Pressure and Augmentation of the Pressor Response to ANG II in CYP1A1-REN2 Transgenic Rats , 2010, The American journal of the medical sciences.

[5]  N. Hosten,et al.  Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism , 2009, American journal of physiology. Heart and circulatory physiology.

[6]  D. Burkhoff,et al.  The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences? , 2008, European heart journal.

[7]  V. Demarco,et al.  Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. , 2008, American journal of physiology. Endocrinology and metabolism.

[8]  J. Sowers,et al.  Female gender is associated with decreased oxidative stress and increased insulin‐stimulated glucose uptake in skeletal muscle in TGR(mRen‐2)27 rats , 2008 .

[9]  Jianwen Wang,et al.  Preserved left ventricular twist and circumferential deformation, but depressed longitudinal and radial deformation in patients with diastolic heart failure. , 2007, European heart journal.

[10]  K. Bernstein,et al.  Is Angiotensin II a Direct Mediator of Left Ventricular Hypertrophy?: Time for Another Look , 2007, Hypertension.

[11]  J. Mullins,et al.  Renal vascular and tubulointerstitial inflammation and proliferation in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. , 2007, American journal of physiology. Renal physiology.

[12]  B. Janssen,et al.  Interruption of Wnt Signaling Attenuates the Onset of Pressure Overload-Induced Cardiac Hypertrophy , 2007, Hypertension.

[13]  H. S. Struijker Boudier,et al.  Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age , 2007, Journal of hypertension.

[14]  V. Tesar,et al.  AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension , 2006, Journal of hypertension.

[15]  J. Mullins,et al.  Hypertension, kidney, and transgenics: a fresh perspective. , 2006, Physiological reviews.

[16]  J. Mullins,et al.  Enhanced tubuloglomerular feedback in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. , 2005, American journal of physiology. Renal physiology.

[17]  M. Schellings,et al.  Matricellular proteins in the heart: possible role during stress and remodeling. , 2004, Cardiovascular research.

[18]  R. Duisters,et al.  Thrombospondin-2 Is Essential for Myocardial Matrix Integrity: Increased Expression Identifies Failure-Prone Cardiac Hypertrophy , 2004, Circulation research.

[19]  D. J. Veldhuisen,et al.  Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27 , 2004, Journal of Molecular Medicine.

[20]  A. Pessina,et al.  Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. , 2003, Journal of the American College of Cardiology.

[21]  M. Bader.  Role of the local renin-angiotensin system in cardiac damage: a minireview focussing on transgenic animal models. , 2002, Journal of molecular and cellular cardiology.

[22]  J. Mullins,et al.  Controlled Hypertension, a Transgenic Toggle Switch Reveals Differential Mechanisms Underlying Vascular Disease* , 2001, The Journal of Biological Chemistry.

[23]  Y. Pinto,et al.  Effects of angiotensin II subtype 1 receptor blockade on cardiac fibrosis and sarcoplasmic reticulum Ca2+ handling in hypertensive transgenic rats overexpressing the Ren2 gene , 2001, Journal of hypertension.

[24]  Y. Pinto,et al.  Reduction in Left Ventricular Messenger RNA for Transforming Growth Factor &bgr;1 Attenuates Left Ventricular Fibrosis and Improves Survival Without Lowering Blood Pressure in the Hypertensive TGR(mRen2)27 Rat , 2000, Hypertension.

[25]  C. Haley,et al.  Genetic mapping of modifier loci affecting malignant hypertension in TGRmRen2 rats. , 1999, Kidney international.

[26]  J. Mullins,et al.  Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27 , 1998, Journal of hypertension.

[27]  J. Ménard,et al.  Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. , 1996, The Journal of clinical investigation.

[28]  Shokei Kim,et al.  Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. , 1995, Hypertension.

[29]  J. Mullins,et al.  Spontaneous development of malignant phase hypertension in transgenic Ren-2 rats. , 1994, Kidney international.

[30]  J. Damoiseaux,et al.  Rat macrophage lysosomal membrane antigen recognized by monoclonal antibody ED1. , 1994, Immunology.

[31]  A. Danser,et al.  Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. , 1994, Hypertension.

[32]  D. Ganten,et al.  Role of Tissue Renin in the Pathophysiology of Hypertension in TGR(mREN2)27 Rats , 1992, Hypertension.

[33]  H. Gröne,et al.  Generation of GPI-linked CCL5 based chemokine receptor antagonists for the suppression of acute vascular damage during allograft transplantation. , 2006, Protein engineering, design & selection : PEDS.

[34]  J. Omens,et al.  Myocardial remodeling in hypertensive Ren-2 transgenic rats. , 1995, Hypertension.